Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
compound cerebroprotein hydrolysate and ganglioside sodium injection
- Development stage
- Unknown
- Lead developer
- Buchang Pharmaceuticals
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
FuFangNaoTaiJieGan Glucose Injection is a combination therapeutic developed by Shanxi Buchang Pharmaceutical, primarily indicated for the treatment of cerebral vascular diseases, including stroke and traumatic brain injury. The formulation consists of cerebroprotein hydrolysate—a mixture of peptides and amino acids derived from porcine brain tissue—and ganglioside sodium. Cerebroprotein hydrolysate provides neurotrophic support and promotes neuronal survival, while gangliosides are essential components of nerve cell membranes that facilitate nerve repair, neuroplasticity, and functional recovery following central nervous system damage. The drug is administered via intravenous injection in a glucose solution.
- Brand names
- FuFangNaoTaiJieGan Glucose Injection
- Other names
- Compound Cerebroprotein Hydrolysate and Ganglioside InjectionFufang Naotaijieganzhi Putangtang Zhusheye
02
Targets
NTRK2 (Tropomyosin-related kinase receptor type B)NTRK1 (Tropomyosin-related receptor kinase A)
Beyond the preview
Go deeper on compound cerebroprotein hydrolysate and ganglioside sodium injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on compound cerebroprotein hydrolysate and ganglioside sodium injection.